These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 30926636)

  • 1. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
    Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
    Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
    Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
    Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
    Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
    Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
    Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
    Schwaederlé MC; Patel SP; Husain H; Ikeda M; Lanman RB; Banks KC; Talasaz A; Bazhenova L; Kurzrock R
    Clin Cancer Res; 2017 Sep; 23(17):5101-5111. PubMed ID: 28539465
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
    Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
    Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
    Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
    Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Patel SP; Harismendy O; Ikeda M; Parker BA; Kurzrock R
    Clin Cancer Res; 2016 Nov; 22(22):5497-5505. PubMed ID: 27185373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.
    Charo LM; Eskander RN; Okamura R; Patel SP; Nikanjam M; Lanman RB; Piccioni DE; Kato S; McHale MT; Kurzrock R
    Mol Oncol; 2021 Jan; 15(1):67-79. PubMed ID: 32881280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
    Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
    Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
    Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
    Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
    Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
    Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.